Filtered By:
Drug: Temodar
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 1478 results found since Jan 2013.
The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients
CONCLUSION: According to the literature in our study, a multidisciplinary and intensive treatment approach using modern techniques improved the OS of glioblastoma patients. Furthermore, larger RT fields were not associated with better outcomes in glioblastoma patients. As a result, lymphocyte-sparing RT may be more beneficial in increasing patients\' compliance to adjuvant TMZ, which is an important prognostic factor of OS.PMID:37528719 | DOI:10.5137/1019-5149.JTN.40460-22.3
Source: Turkish Neurosurgery - August 2, 2023 Category: Neurosurgery Authors: Niyazi Volkan Demircan Ozge Petek Erpolat Caglar Guzel Ertugrul Senturk Huseyin Bora Eray Karahacioglu Source Type: research
Aggressive pituitary adenoma and pituitary carcinoma
Orv Hetil. 2023 Jul 30;164(30):1167-1175. doi: 10.1556/650.2023.32832. Print 2023 Jul 30.ABSTRACTAnterior pituitary tumours, once considered benign neoplasms, may rarely have aggressive behaviour and can even metastasize. The current guideline of the European Society of Endocrinology defines aggressive pituitary adenomas as radiologically invasive tumours with an unusually rapid growth rate and frequent relapses despite the optimal use of standard therapies. Currently, there is not any single, well-defined pathological marker of malignancy. Pituitary carcinomas are thus clinically defined by the presence of craniospinal or...
Source: Orvosi Hetilap - July 30, 2023 Category: General Medicine Authors: Mikl ós Tóth Source Type: research
Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs
Biomed Pharmacother. 2023 Jul 25;165:115187. doi: 10.1016/j.biopha.2023.115187. Online ahead of print.ABSTRACTBrain tumors, which are highly malignant, pose a significant threat to health and often result in substantial rates of mortality and morbidity worldwide. The brain cancer therapy has been challenging due to obstacles such as the BBB, which hinders effective delivery of therapeutic agents. Additionally, the emergence of drug resistance further complicates the management of brain tumors. TMZ is utilized in brain cancer removal, but resistance is a drawback. ncRNAs are implicated in various diseases, and their involve...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 27, 2023 Category: Drugs & Pharmacology Authors: Aryan Rezaee Pooya M Tehrany Farimah Jafari Tirabadi Negin Sanadgol Asal Sadat Karimi Atra Ajdari Sepideh Eydivandi Sara Etemad Romina Rajabi Parham Rahmanian Ramin Khorrami Noushin Nabavi Amir Reza Aref Xiaoping Fan Rongjun Zou Mohsen Rashidi Mohammad Ar Source Type: research
Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma
CONCLUSIONS: These results establish LP-184 as a promising chemotherapeutic for GBM with enhanced efficacy in intrinsic or spironolactone-induced TC-NER deficient tumors.PMID:37494541 | DOI:10.1158/1078-0432.CCR-23-0673
Source: Cell Research - July 26, 2023 Category: Cytology Authors: Bachchu Lal Aditya Kulkarni Joseph McDermott Rana Rais Jesse Alt Ying Wu Hernando Lopez-Bertoni Sophie Sall Umesh Kathad Jianli Zhou Barbara S Slusher Kishor Bhatia John Laterra Source Type: research
